行情

CTMX

CTMX

CytomX医疗
NASDAQ

实时行情|Nasdaq Last Sale

9.25
+0.23
+2.55%
盘前: 9.15 -0.1 -1.08% 09:04 09/17 EDT
开盘
9.00
昨收
9.02
最高
9.37
最低
8.91
成交量
16.49万
成交额
--
52周最高
19.75
52周最低
8.07
市值
4.20亿
市盈率(TTM)
-4.2038
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CTMX 新闻

  • 苹果140亿美元上诉案开庭:称欧盟滥用职权 违背常识
  • 新浪科技.2小时前
  • 瑞银:港交所可以尝试号召伦交所股东召开临时大会
  • 新浪财经.2小时前
  • 美交通部宣布首批自动驾驶研究补助金去向 三州入围
  • TechWeb.3小时前
  • 亚马逊被曝“做手脚”推销其高利润率产品
  • 澎湃新闻.3小时前

更多

所属板块

生物技术和医学研究
+0.98%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

CTMX 简况

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
展开

Webull提供CytomX Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。